<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00302263</url>
  </required_header>
  <id_info>
    <org_study_id>KF11-282523</org_study_id>
    <nct_id>NCT00302263</nct_id>
  </id_info>
  <brief_title>B181 Metobes-III: Weight Loss Maintenance of a New Bioactive Compound (Metobes-Long)</brief_title>
  <official_title>B181 Metobes-III: Weight Loss Maintenance of a New Bioactive Compound (Metobes-Long)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Metabolife</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <brief_summary>
    <textblock>
      To investigate the 5-hour acute effect on energy expenditure, substrate oxidation and ad&#xD;
      libitum food intake after intake of the Metobes-compound (green tea extract, capsaicin,&#xD;
      tyrosine, caffeine). Furthermore, to investigate if the effect of the Metobes-compound can be&#xD;
      inhibited by blocking the β-adrenergic receptors.&#xD;
&#xD;
      The effect of the Metobes-compound will be investigated by:&#xD;
&#xD;
        1. 5-hour energy expenditure and respiratory quotient (ventilated hood).&#xD;
&#xD;
        2. 5-h change in blood pressure and heart rate&#xD;
&#xD;
        3. 5-h change in sympathetic/parasympathetic ratio.&#xD;
&#xD;
        4. Ad libitum energy intake.&#xD;
&#xD;
        5. Self-reported postprandiel appetite sensations (VAS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects 22 healthy Danish overweight to obese men (BMI between 25 and 35 kg/m2), 18 to 50&#xD;
      years of age. All subjects must be weight stable (within  3-kg) 2 months prior to study&#xD;
      inclusion, non-smoking, non-athletic and have no daily use of medication.&#xD;
&#xD;
      Method&#xD;
&#xD;
      The study is designed as a 4-way crossover, randomised, placebo controlled, double-blind&#xD;
      study. Each treatment will be separated by &gt;1-week washout period. The treatments will&#xD;
      consist of:&#xD;
&#xD;
        1. Bioactive Metobes compound (green tea extract, tyrosine, caffeine and capsaicin) without&#xD;
           calcium together with 5 mg propranolol.&#xD;
&#xD;
        2. Bioactive Metobes compound (green tea extract, tyrosine, caffeine and capsaicin) without&#xD;
           calcium together with 10 mg propranolol.&#xD;
&#xD;
        3. Bioactive Metobes compound (green tea extract, tyrosine, caffeine and capsaicin) without&#xD;
           calcium together with a placebo tablet for propranolol (microcrystalline cellulose).&#xD;
&#xD;
        4. Placebo for the Metobes compound (microcrystalline cellulose) together with a placebo&#xD;
           tablet for propranolol (microcrystalline cellulose).&#xD;
&#xD;
      On each test day body weight and composition will be assessed. All subjects will undergo a&#xD;
      5-h post dose assessment of energy expenditure by indirect calorimetry in a ventilated hood.&#xD;
      Subjective appetite sensations, ECG and dual measures of blood pressure/heart rate will be&#xD;
      assessed every 30 minutes. After completed respiratory measurements the subjects will be&#xD;
      served an ad libitum lunch meal (pasta salad).&#xD;
&#xD;
      All subjects shall collect all urine excreted during the respiratory measurements. Urine&#xD;
      samples will be analyzed for nitrogen content and content of catecholamines.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date>April 2005</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Energy expenditure</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>substrate oxidation</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>catecholmamines</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>energy intake</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>subjective appetite sensations</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>sympathetic/parasympathetic ratio</measure>
  </primary_outcome>
  <enrollment>22</enrollment>
  <condition>Obesity</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metobes-compound</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  21 healthy Danish normal-weight to obese men (BMI between 20 and 35 kg/m2), 18 to 50&#xD;
             years of age. All subjects must be weight stable (within  3-kg) 2 months prior to&#xD;
             study inclusion, non-smoking, non-athletic and have no daily use of medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  They will be excluded if they do not meet the inclusion criteria and/or the blood&#xD;
             pressure is above 165/95 mmHg and/or the ECG is abnormal.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Kondrup, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Human Nutrition, The Royal Veterinary and Agricultural University, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Human Nutrition, The Royal Veterinary and Agricultural University</name>
      <address>
        <city>Frederiksberg</city>
        <zip>1958</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2005</verification_date>
  <study_first_submitted>March 13, 2006</study_first_submitted>
  <study_first_submitted_qc>March 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2006</study_first_posted>
  <last_update_submitted>March 13, 2006</last_update_submitted>
  <last_update_submitted_qc>March 13, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2006</last_update_posted>
  <keyword>Green tea</keyword>
  <keyword>capsaicin</keyword>
  <keyword>tyrosine</keyword>
  <keyword>caffeine</keyword>
  <keyword>energy expenditure</keyword>
  <keyword>catecholamines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

